Gavorník Peter, Dukát Andrej, Gašpar Ľudovít, Medová Denisa, Faktorová Xénia, Gavorníková Eva
Vnitr Lek. 2015 Jul-Aug;61(7-8):660-9.
Erectile dysfunction is a highly prevalent and progressive condition affecting the quality of life of man and his sexual partner. Evidence is accumulating in favour of erectile dysfunction as a sign of a genitovascular disease (GVD) in the majority of patients. Erectile dysfunction may be considered as the clinical manifestation of a organovascular disease affecting penis (male genitovascular disease - MGVD) as well as angina pectoris is the typical manifestation of a vascular disease affecting coronary arteries of a heart (cardiovascular disease - CVD). Several studies confirm the assumption that erectile dysfunction symptoms were found to come prior to cardiovascular disease symptoms in 60-95 % of CVD patients with mean interval of 2-3 years and likewise of all organovascular diseases (OVD). Four potent selective PDE5Is have been approved by the EMA for the treatment of erectile dysfunction. Physicians should systematically look for erectile dysfunction in any male with vascular risk factors.
勃起功能障碍是一种高度普遍且呈进行性发展的疾病,会影响男性及其性伴侣的生活质量。越来越多的证据表明,在大多数患者中,勃起功能障碍是生殖血管疾病(GVD)的一种体征。勃起功能障碍可被视为影响阴茎的器官血管疾病(男性生殖血管疾病 - MGVD)的临床表现,就如同心绞痛是影响心脏冠状动脉的血管疾病(心血管疾病 - CVD)的典型表现一样。多项研究证实了以下假设:在60% - 95%的心血管疾病患者中,勃起功能障碍症状先于心血管疾病症状出现,平均间隔为2 - 3年,所有器官血管疾病(OVD)患者亦是如此。欧洲药品管理局(EMA)已批准四种强效选择性磷酸二酯酶5抑制剂(PDE5Is)用于治疗勃起功能障碍。医生应系统地筛查任何有血管危险因素的男性是否存在勃起功能障碍。